BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Corcept, Clovis Score Wins in Advanced Ovarian Cancer

  It’s a promising day for advanced ovarian cancer research as two biopharma companies achieved positive results. Here’s what you need to know about research.

  March 31, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Rani is Opening Doors in Biosimilars, Challenging Humira and Others

  San Jose-based Rani Therapeutics reported its fourth quarter and full-year 2021 financial results. The company hit major milestones this year, including the recent launch of the RaniPill High Capacity,

  March 31, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Business

  Sanofi in the News: Grand Expectations and Paul Hudson’s $12.3M Salary

  Sanofi inked a pact with IGM Biosciences that could pass $6 billion. However, Sanofi CEO Paul Hudson’s pay had a drop of about 3.7%, according to the company’s annual filing.

  March 31, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Narrowing Focus to Rett and GAN, Taysha is Reducing Workforce by 35%

  Taysha Gene Therapies announced that it will focus its efforts on clinical programs targeting Rett Syndrome and giant axonal neuropathy (GAN), resulting in a 35% reduction in its workforce.

  March 31, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  With Positive Phase II Results, Cerevance Proves Concept in Parkinson’s

  Cerevance reported positive clinical trial results for CVN424, an experimental treatment for Parkinson’s disease.

  March 31, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  CytoDyn Hit with Two Clinical Holds as Optimism Appears to Wane

  The U.S. FDA placed a partial hold on CytoDyn’s HIV program and a full clinical hold on its COVID-19 program in the U.S.

  March 31, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Dr. Arthur Riggs Leaves a Legacy in Biotech, Diabetes Research

  The man who many consider the father of synthetic insulin treatment for diabetes, as well as a founder of modern biotechnology- Dr. Arthur Riggs - died this week at the age of 82.

  March 31, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Drug Development

  Research Roundup: Scientists May Have Solved CAR-T Turnaround Challenge

  CAR-T cell therapy is still a time-consuming and expensive process. But researchers may have just solved the turnaround-time challenge for CAR-T.

  March 31, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Origami Brings Protein Degradation to Neurodegenerative Disorders

  Origami’s precision technology platform, Oricision™, is focused on diseases that affect the central nervous system rather than oncology.

  March 31, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Business

  Workforce Cuts Abound at Zealand Pharma, Merck and Orchard

  Several employees at three biopharma firms are not having a very good week, as Zealand Pharma, Merck and Orchard Therapeutics all announced job cuts.

  March 31, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN